BackApimeds Pharmaceuticals US Overview

Apimeds Pharmaceuticals US Receivables

Track Apimeds Pharmaceuticals US's receivables ($0) with charts, peers, and YoY trends.

Get informed when a big investor buys or sells

+ Follow
Receivables
$0.00

Peer trimmed avg / median

Loading

Apimeds Pharmaceuticals US Receivables History

Loading

Apimeds Pharmaceuticals US vs. peers: Receivables Comparison

Loading

Apimeds Pharmaceuticals US Receivables Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Balance Sheet Breakdown

Current CashShort Term InvestmentsReceivablesInventoryOther Current AssetsCurrent AssetsLong Term InvestmentsProperty Plant EquipmentGoodwillIntangible AssetsOther AssetsTotal AssetsNet Tangible AssetsAccounts PayableOther Current LiabilitiesTotal Current LiabilitiesLong Term DebtOther LiabilitiesMinority InterestTotal Liabilities

Apimeds Pharmaceuticals US (APUS) FAQ

Apimeds Pharmaceuticals US (APUS) currently reports a receivables of $0 as of June 2026. In the prior-year period, the figure was $0. Use the charts on this page to explore Apimeds Pharmaceuticals US's receivables history and peer comparisons.

Apimeds Pharmaceuticals US's receivables changed from $0 to $0 (period ending June 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Apimeds Pharmaceuticals US reported $0 in receivables as of June 2026. In the prior-year period, the figure was $0. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current receivables of $0, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Apimeds Pharmaceuticals US, and consider following APUS for alerts when major investors trade the stock.